hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06323252, orgStudyIdInfo id: MastihaOil-HT, briefTitle: A Study on the Effects of Mastiha Oil in Adults With Hypertriglyceridemia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2025-10-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Harokopio University, class: OTHER, descriptionModule briefSummary: Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of Mastiha. Its composition is high in bioactive ingredients (such as terpenic acids and polyphenols) which have proven anti-inflammatory, antioxidant, cardioprotective, chemoprotective and antimicrobial properties. The aim of this study is to determine the effect of Mastiha oil in adults with Hypetriglyceridemia. 100 participants will be allocated to two groups, (50 in intervention group and 50 in control group). Mastiha oil will be provided in the form of soft gel capsules to the intervention group, whereas the control group will not consume the capsules. Both groups will receive standard nutritional counselling. The intervention will last 3 months.The effects of the intervention will be evaluated via clinical and laboratory markers., conditionsModule conditions: Hypertriglyceridemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: MastihaOil, interventions name: nutritional counsel, outcomesModule primaryOutcomes measure: Change in blood triglycerides, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323239, orgStudyIdInfo id: SBRT/LDRT+PD-1+GP for r/mNPC, briefTitle: SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2028-04-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients., conditionsModule conditions: Nasopharyngeal Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 148, type: ESTIMATED, armsInterventionsModule interventions name: SBRT, interventions name: Low-dose Radiotherapy (LDRT), interventions name: Toripalimab, interventions name: Gemcitabine, interventions name: Cisplatin, interventions name: IMRT, outcomesModule primaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Objective Response Rate, secondaryOutcomes measure: Disease Control Rate, secondaryOutcomes measure: Adverse Events, secondaryOutcomes measure: QoL, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, city: Guangzhou, state: Guangdong, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06323226, orgStudyIdInfo id: 2024-312-1, briefTitle: The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-01-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: West China Hospital, class: OTHER, descriptionModule briefSummary: This study is conducted in critically ill children with sepsis with a five years follow-up. We aim to investigate the impact of sepsis on long-term outcomes including growth, neurodevelopment, survival rate, quality of life., conditionsModule conditions: Sepsis, conditions: Children, Only, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, outcomesModule primaryOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 0 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: West China Hospital of Sichuan University, status: RECRUITING, city: Chendu, state: Sichuan, country: China, contacts name: Ji Yi, Doctor, role: CONTACT, hasResults: False
protocolSection identificationModule nctId: NCT06323213, orgStudyIdInfo id: SSGJ-610-BA-III-01, briefTitle: Efficacy and Safety Study of 610 in Patients With Severe Asthma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma., conditionsModule conditions: Asthma, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 480, type: ESTIMATED, armsInterventionsModule interventions name: 610, interventions name: Placebo, outcomesModule primaryOutcomes measure: Annualized rate of severe exacerbation events, secondaryOutcomes measure: Time to first severe exacerbation event, secondaryOutcomes measure: Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit, secondaryOutcomes measure: Change from baseline in ACQ score, secondaryOutcomes measure: Change from baseline in ST. GEORGE'S Respiratory Questionnaire(SGRQ), secondaryOutcomes measure: Change in pre-bronchodilator forced expiratory volume (FEV1), secondaryOutcomes measure: Assessment of adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323200, orgStudyIdInfo id: 202400221B0, briefTitle: Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA, acronym: LVA, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-09, primaryCompletionDateStruct date: 2023-03, completionDateStruct date: 2023-03, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Chang Gung Memorial Hospital, class: OTHER, descriptionModule briefSummary: This study aimed to address the impact of lymphedema duration on the quality of lymphatic vessels as well as the outcome after LVA using propensity score matching., conditionsModule conditions: Lymphedema, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 189, type: ACTUAL, armsInterventionsModule interventions name: lymphaticovenous anastomosis, outcomesModule primaryOutcomes measure: Volume change after LVA., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06323187, orgStudyIdInfo id: 4656, briefTitle: Optimization of Cervical Collections in Pregnancy, acronym: OCCP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2031-02-28, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Dr. Sascha Drewlo, class: OTHER, descriptionModule briefSummary: Fetal cells are not easily obtained from pregnant patients; this curtails testing to assess the health of the fetus and the mother. Currently, the only way of diagnosing fetal genetic or chromosomal abnormalities is by invasive techniques, such as chorionic villous sampling (CVS) and amniocentesis performed at 10 to 13 weeks and after 15 weeks of gestation, respectively. Although small, there is a risk for fetal loss with these procedures. Transcervical cell sampling (TCS), similar to a Pap smear, is a platform that meets the requirements for prenatal genetic testing (genetic testing with fetal cells obtained before birth), as well as diagnosis of maternal pregnancy complication, at a very early stage of pregnancy (as early as 5 weeks) and carries low risk for the mother and the developing fetus.This study will examine cervical fluid collected using various noninvasive methods for TCS in pregnant women. The number of placental cells will be assessed against similarly obtained samples from nonpregnant women of reproductive age who lack cells derived from a placenta. Participating volunteers will provide written informed consent. Only standard medical procedures and approved devices will be used for collection of cervical fluid, minimizing risk to the participants and their fetuses. No test results or other benefits will be available to the participants., conditionsModule conditions: Cervix; Pregnancy, conditions: Inherited Genetic Conditions (Diagnosis), conditions: Preeclampsia, conditions: Fetal Growth Retardation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 2600, type: ESTIMATED, armsInterventionsModule interventions name: Cervical Sampling, outcomesModule primaryOutcomes measure: Cellular content, primaryOutcomes measure: Cell-free content, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323148, orgStudyIdInfo id: ECTOP-1022, briefTitle: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2029-03-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: This study plans to conduct ctDNA testing on EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients after radical surgery (R0 resection). Patients with positive ctDNA testing will receive standard treatment according to clinical guidelines, while patients with negative ctDNA testing will be assessed based on comprehensive clinical and pathological characteristics. After receiving or not receiving standard adjuvant chemotherapy, patients will be randomly assigned in a 1:1 ratio to either the observation follow-up group (experimental group) or the osimertinib adjuvant treatment group (control group). The aim is to explore whether observation follow-up for patients with negative ctDNA after surgery has a prognosis non-inferior to osimertinib treatment, and to investigate the disease-free survival rate of EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients with positive ctDNA after surgery receiving osimertinib adjuvant treatment, providing more precise treatment guidance for adjuvant therapy in this specific type of NSCLC patients with EGFR mutation-positive tumors., conditionsModule conditions: Lung Cancer, conditions: EGFR Gene Mutation, conditions: Minimal Residual Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 226, type: ESTIMATED, armsInterventionsModule interventions name: Osimertinib, interventions name: No adjuvant therapy, outcomesModule primaryOutcomes measure: The 3-year Disease-Free Survival (DFS) rate between the observation group and the osimertinib treatment group., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06323135, orgStudyIdInfo id: 2019-725, briefTitle: Nutrition Assessment in Advanced Cancer Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-09-17, primaryCompletionDateStruct date: 2023-09-11, completionDateStruct date: 2023-09-11, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: West China Hospital, class: OTHER, descriptionModule briefSummary: The goal of this retrospective observational study is to evaluate the prognostic value of nutrition assessment tool in advanced cancers. We aim to evaluate the clinical utility of nutrition assessment tool in predicting the clinical outcomes of cancer patients, which would help the clinicians to make tailored decision for this population., conditionsModule conditions: Advanced Cancer, conditions: Nutrition Aspect of Cancer, conditions: Prognostic Cancer Model, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 2115, type: ACTUAL, outcomesModule primaryOutcomes measure: All-cause mortality, secondaryOutcomes measure: length of stay in hospital, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: West China Hospital, Sichuan Universit, city: Chengdu, state: Sichuan, zip: 610041, country: China, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06323122, orgStudyIdInfo id: Plating Techniques 2023, briefTitle: A Comparative Study Between Three Different Plating Techniques in Management of Mandibular Parasymphyseal Fractures., statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2023-10-01, completionDateStruct date: 2023-12-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: October 6 University, class: OTHER, descriptionModule briefSummary: The main goal in management of mandibular fractures is to restore the pre-injury form and function, with the least disability and shortest recovery period., conditionsModule conditions: Mandibular Fractures, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: 2.0 miniplates, interventions name: 2.3 high profile miniplates, interventions name: 3D miniplates, outcomesModule primaryOutcomes measure: Surgery Time, secondaryOutcomes measure: complication, secondaryOutcomes measure: fracture stability, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: October 6U, city: Cairo, zip: 12566, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06323109, orgStudyIdInfo id: 2023-1331, secondaryIdInfos id: A196200, type: OTHER, domain: UW Madison, secondaryIdInfos id: Protocol Version 12/21/23, type: OTHER, domain: UW Madison, briefTitle: US Imaging for the Assessment of LUTS, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-28, primaryCompletionDateStruct date: 2026-01-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, collaborators name: Wisconsin Partnership Program, descriptionModule briefSummary: The purpose of this research is to develop an ultrasound (US) based urodynamics (UDS) evaluation of voiding based on successful magnetic resonance imaging (MRI)-UDS evaluation. Both US and MRI are non-invasive imaging techniques, but US is a more cost-effective and widely available technology. 80 participants will be enrolled and will be on study for up to 2.5 hours (1.5 hour MRI and 1 hour US)., conditionsModule conditions: Lower Urinary Tract Symptoms, conditions: BPH, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: MRI-UDS; US-UDS; MCUD, outcomesModule primaryOutcomes measure: MRI Urodynamics - Change in Bladder Volume, primaryOutcomes measure: MRI Urodynamics - Change in Urine Velocity, primaryOutcomes measure: MRI Urodynamics - Change in Pressure, primaryOutcomes measure: Bladder outlet obstruction index (BOOI), primaryOutcomes measure: Bladder contractility index (BOI), primaryOutcomes measure: International Prostate Symptom Score (IPSS), eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Wisconsin, status: RECRUITING, city: Madison, state: Wisconsin, zip: 53705, country: United States, contacts name: Gemma Gliori, MS, role: CONTACT, email: ggliori@uwhealth.org, contacts name: Suzanne Hanson, BS, role: CONTACT, email: shanson@uwhealth.org, contacts name: Alejandro Roldan-Alzate, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Wade Bushman, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Matt Grimes, MD, role: SUB_INVESTIGATOR, contacts name: Giuseppe Toia, MD, role: SUB_INVESTIGATOR, contacts name: Ivan Rosado-Mendez, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06323096, orgStudyIdInfo id: AR13067824, briefTitle: Development of Clinical Decision Support System for Severe Patients With Polytrauma, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-12-01, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Semey State Medical University, class: OTHER, collaborators name: Ministry of Science and Higher Education of the Republic of Kazakhstan, descriptionModule briefSummary: The goal of this observational study is to develop a Clinical Decision Support System for severe patients with polytrauma. The main questions it aims to answer are:* Is it possible to predict the development of systemic inflammatory response syndrome for the next 24 h after admission?* Is it possible to predict the development of blood loss \>25% of blood volume for the next 24 h after admission?* Is it possible to predict the development of acute traumatic coagulopathy for the next 24 h after admission?* Is it possible to predict the development of pneumonia in polytrauma patients?* Is it possible to predict the outcome in polytrauma patients?No intervention is planned for this study., conditionsModule conditions: Polytrauma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Prediction of SIRS, primaryOutcomes measure: Rate of ATC prediction in the 24 h after admission using the developed CDSS., primaryOutcomes measure: Rate of hemorrage prediction in the 24 h after admission using the developed CDSS., primaryOutcomes measure: Rate of pneumonia prediction using the developed CDSS., eligibilityModule sex: ALL, minimumAge: 28 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Emergency Hospital, status: RECRUITING, city: Semey, state: Abai, zip: 071400, country: Kazakhstan, contacts name: Alexander Prokazyuk, MD, role: CONTACT, phone: +77071891849, email: prokazyuk.md@yandex.ru, geoPoint lat: 50.42675, lon: 80.26669, hasResults: False
protocolSection identificationModule nctId: NCT06323083, orgStudyIdInfo id: 006, briefTitle: The Effect of Emotional Freedom Technique on Perceived Stress and General Self-Efficacy in Nursing Students, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-07, primaryCompletionDateStruct date: 2022-11-28, completionDateStruct date: 2023-06-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Selcuk University, class: OTHER, descriptionModule briefSummary: The study was conducted to determine the effect of Emotional Freedom Technique (EFT) on perceived stress and general self-efficacy in obstetrics and gynecology nursing lesson in undergraduate nursing students with fear of birth.The samples were applied to undergraduate nursing students satisfying the research criteria in a state university nursing faculty in Konya at November 2022., conditionsModule conditions: Emotion Regulation, conditions: Stress, conditions: Self Efficacy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study was designed to be randomly controlled., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: Emotional Freedom Technique, outcomesModule primaryOutcomes measure: General Self-Efficacy Scale, primaryOutcomes measure: Perceived Stress Scale, primaryOutcomes measure: The Subjective Units of Distress Scale, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Selcuk University, city: Konya, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False